But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.
Deals will come into even greater focus after the failure of ligelizumab, one of the group’s brightest pipeline hopes.
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.